KEYNOTE-689: A Phase 3 Study of Neoadjuvant and Adjuvant Pembrolizumab Plus Standard of Care (SOC) in Resectable, Locally Advanced (LA) Head and Neck Squamous Cell Carcinoma (HNSCC)

Introduction: The randomized, open-label, phase 3 KEYNOTE-689 trial (NCT03765918) is designed to evaluate neoadjuvant pembrolizumab and adjuvant pembrolizumab plus SOC in previously untreated LA HNSCC.